Vitamin D Council needs your help...

Tax-deductible!

Together we can end the illness and disease caused by the worldwide epidemic of vitamin D deficiency.

About Vitamin D Council

Contact Vitamin D Council

Sponsor Vitamin D Council

Follow us on:

Vitamin D Products

(off-site)

These companies donate to the Vitamin D Council.

D-Lite, Renew, & SunSplash UV/Tanning Systems
In-Home ZRT Vitamin D Blood Test Kit
Get Premium Quality Vitamin D Supplements at Great Prices
Vitamin D3 Plus™ from Bio-Tech — contains the cofactors Vitamin D needs to work properly.

Vitamin D Research

back to research menu

Prostate Cancer

Correlations between meteorological parameters and prostate cancer. Int J Health Geogr. 2010 Apr 21;9(1):19.
Vitamin D and prostate cancer: The role of membrane initiated signaling pathways in prostate cancer progression. J Steroid Biochem Mol Biol. 2010 Apr 14.
Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010 Apr 10.
Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev. 2010 Apr;36(2):122–30. Review.
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology. 2010 Apr;151(4):1409–17.
Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J Steroid Biochem Mol Biol. 2010 Mar 27.
A combined pretreatment of 1,25-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells. J Steroid Biochem Mol Biol. 2010 Mar 7.
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology. 2010 Mar;151(3):896–908.
Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer. 2010 Mar;46(5):932–6.
25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):162–70.
Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010 Jan–Feb;16(1):1–9.
Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer. 2010 Jan 29;17(1):R19–38.
1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics. 2010 Jan 13;11:26.
The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: Operational networks and tissue-specific growth control. Biochem Pharmacol. 2010 Jan 1;79(1):1–9. Review.
Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet. 2009 Dec 4;10:125.
Gene polymorphisms and prostate cancer: the evidence. BJU Int. 2009 Dec;104(11):1560–72. Review.
Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009 Dec;33(6):435–45.
The promiscuous receptor. BJU Int. 2009 Nov;104(9):1204–7.
Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci. 2009 Oct;18(10):2036–42.
Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int J Cancer. 2009 Sep 15;125(6):1414–23.
How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Res. 2009 Sep;29(9):3675–84. Review.
Expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alphaOHase, CYP27B1) splice variants in HaCaT keratinocytes and other skin cells: modulation by culture conditions and UV-B treatment in vitro. Anticancer Res. 2009 Sep;29(9):3659–67.
Synthesis and biological activities of 14-epi-MART-10 and 14-epi-MART-11: implications for cancer and osteoporosis treatment. Anticancer Res. 2009 Sep;29(9):3563–9.
Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res. 2009 Sep;29(9):3547–53.
The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009 Sep;29(9):3511–36. Review.
Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009 Sep;104(6):800–5.
Serum calcium and the risk of prostate cancer. Cancer Causes Control. 2009 Sep;20(7):1205–14.
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2009 Aug 28.
Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur J Cancer Prev. 2009 Aug 26.
Growth/differentiation factor-15 inhibits differentiation into osteoclasts-A novel factor involved in control of osteoclast differentiation. Differentiation. 2009 Aug 18.
Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci. 2009 Jul 29.
Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control. 2009 Jul 4.
Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009 Jul;19(7):468–83.
Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009 Jul;30(7):1170–80.
Prevalence and correlates of vitamin D status in African American men. BMC Public Health. 2009 Jun 18;9(1):191.
Vitamin d pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1929–33.
Regulation of human vitamin D3 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009 Jun;75(6):1392–9.
Treatment of K562 cells with 1,25-dihydroxyvitamin D(3) induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCL(XL), and p21. Ann Hematol. 2009 May 28.
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer. 2009 May 27.
Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol. 2009 May 15;169(10):1223–32.
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009 May;30(5):769–76.
1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 2009 May;150(5):2046–54.
Vitamin D Gene Pathway Polymorphisms and Risk of Colorectal, Breast, and Prostate Cancer. Annu Rev Nutr. 2009 Apr 21.
Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis. 2009 Apr 7.
The role of the calcium-sensing receptor in bone biology and pathophysiology. Curr Pharm Biotechnol. 2009 Apr;10(3):289–301.
Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. Endocrinology. 2009 Apr;150(4):1580–7.
Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int. 2009 Mar;103(6):753–7.
Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009 Feb 10;100(3):450–4.
Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int J Cancer. 2008 Dec 15;123(12):2899–901.
Geographic location and vitamin D synthesis. Mol Aspects Med. 2008 Dec;29(6):453–61.
The vitamin D deficiency pandemic and consequences for nonskeletal health: Mechanisms of action. Mol Aspects Med. 2008 Dec;29(6):361–8. Review.
Vitamin D may reduce prostate cancer metastasis by several mechanisms including blocking Stat3. Am J Pathol. 2008 Nov;173(5):1589–90. Letter.
Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol. 2008 Nov;112(1–3):151–6.
A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem Mol Biol. 2008 Nov;112(1–3):47–54.
Association of Genetic Polymorphisms in Vitamin D Receptor Gene and Susceptibility to Sporadic Prostate Cancer. Exp Biol Med (Maywood). 2008 Oct 10.
Inactivation of the Human Vitamin D Receptor by Caspase-3. Endocrinology. 2008 Oct 1.
Vitamin D and Sunlight: Strategies for Cancer Prevention and Other Health Benefits. Clin J Am Soc Nephrol. 2008 Sep;3(5):1548–54.
Dietary supplement use among elderly, long-term cancer survivors. J Cancer Surviv. 2008 Sep;2(3):138–48.
Vitamin D and prostate cancer risk—a less sunny outlook? J Natl Cancer Inst. 2008 Jun 4;100(11):759–61. Review.
Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008 Jun 4;100(11):796–804.
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008 Apr 15;167(8):925–34.
Prevalence & potential significance of vitamin D deficiency in Asian Indians. Indian J Med Res. 2008 Mar;127(3):229–38. Review.
Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs). Adv Exp Med Biol. 2008;624:203–14. Review.
Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol. 2007 Dec 1;166(11):1259–69.
Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2623–30.
Prostate cancer survival is dependent on season of diagnosis. Prostate. 2007 Sep 1;67(12):1362–70.
Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer. 2007 Jul;43(11):1701–12.
Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007 Jun 15;67(9):911–23.
Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1283–6.
A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007 Mar;4(3):e103.
An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer. 2007 Mar 1;120(5):1123–8.
Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? Lung Cancer. 2007 Mar;55(3):263–70.
Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):302–7.
Favourable and unfavourable effects of exposure to sunlight. Ned Tijdschr Geneeskd. 2007 Jan 13;151(2):118–22. Review In Dutch.
1,25-Dihydroxyvitamin D(3) regulates genes responsible for detoxification in intestine. Toxicol Appl Pharmacol. 2007 Jan 1;218(1):37–44.
Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer. 2006 Nov 10;6:264.
Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer. 2006 Oct 15;119(8):1902–7.
Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer. 2006 Oct 1;119(7):1530–6.
UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control. 2006 Oct;17(8):1091–101.
Does sunlight prevent cancer? A systematic review. Eur J Cancer. 2006 Sep;42(14):2222–32. Review.
Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol. 2006 Sep;92(1):65–79. Review.
Does sunlight have a beneficial influence on certain cancers? Prog Biophys Mol Biol. 2006 Sep;92(1):132–9. Review.
Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006 Sep;92(1):49–59. Review.
Vitamin D deficiency: A global perspective. Arq Bras Endocrinol Metabol. 2006 Aug;50(4):640–6.
UV radiation and cancer prevention: what is the evidence? Anticancer Res. 2006 Jul–Aug;26(4A):2723–7. Review.
The likely role of vitamin D from solar ultraviolet-B irradiance in increasing cancer survival. Anticancer Res. 2006 Jul–Aug;26(4A):2605–14.
Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006 Jul–Aug;26(4A):2567–72.
A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer. 2006 Jul 15;107(2):266–74.
The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol. 2006 Jun;132(6):408–16.
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006 May 15;106(10):2136–42.
Non-genomic effects of the androgen receptor and Vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells. Steroids. 2006 Apr;71(4):304–9.
The Role of Vitamin D in Cancer Prevention. Am J Public Health. 2006 Feb;96(2):252–61. Review.
A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):203–10.
Prostate cancer risk: the significance of differences in age related changes in serum conjugated and unconjugated steroid hormone concentrations between Arab and Caucasian men. Int Urol Nephrol. 2006;38(1):33–44.
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8680–5.
Ultraviolet Radiation, Vitamin D and Risk of Prostate Cancer and Other Diseases. Photochem Photobiol. 2005 Nov–Dec;81(6):1252–60. Review.
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol. 2005 Sep;174(3):888–92.
Vitamin D and the epidemiology of prostate cancer. Semin Dial. 2005 Jul–Aug;18(4):276–89. Review.
Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr. 2005 May;81(5):1147–54.
Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005 May;35(5):290–304. Review.
Vitamin-D receptor (VDR) gene (Fok-I, Taq-I and Apa-I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Prev. 2005 Apr–Jun;6(2):147–52.
The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005 Mar;16(2):83–95. Review.
Vitamin D and the elderly. Clin Endocrinol (Oxf). 2005 Mar;62(3):265–81. Review.
Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis. 2005;22(3):275–84.
Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis. 2005;22(3):265–73.
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 1;10(23):8018–27.
The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol. 2004 Nov;92(4):317–25. Review.
Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol. 2004 Jul;172(1):12–9. Review.
Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J. 2004 Apr;25(4):447–51.
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004 Apr;15(3):255–65.
Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):546–52.
A multicountry ecologic study of risk and risk reduction factors for prostate cancer mortality. Eur Urol. 2004 Mar;45(3):271–9.
Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control. 2004 Mar;15(2):149–58.
Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients. Adv Perit Dial. 2004;20:203–8.
Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ Mol Mutagen. 2004;43(2):121–7.
Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab. 2003 Nov;14(9):423–30. Review.
Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):597–603.
Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology. 2003 Jun;61(6):1261–5.
Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis. 2003 Apr;24(4):711–7.
Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. Cancer Lett. 2003 Mar 31;192(2):145–9.
CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer. 2003 Mar 24;88(6):928–32.
Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review). Int J Oncol. 2003 Jan;22(1):5–13. Review.
Ecologic studies of solar UVB radiation and cancer mortality rates. Recent Results Cancer Res. 2003;164:371–7. Review.
Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 2003;164:273–88.
Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res. 2003;164:223–37. Review.
Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol. 2002 Aug;147(2):197–213. Review.
25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol. 2002 Jun;81(2):135–40.
Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate. 2002 Apr 1;51(1):30–4.
Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med. 2002 Apr;59(4):257–62.
An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002 Mar 15;94(6):1867–75.
Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int. 2002;68(4):226–31.
Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev. 2002;21(2):147–58. Review.
Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis. 2001 Sep;22(9):1343–7.
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001 Apr 1;61(7):2852–6.
Vitamin D and prostate cancer. J Steroid Biochem Mol Biol. 2001 Jan–Mar;76(1–5):125–34.
Prostate cancer risk and prediagnostic serum 25-hydroxy vitamin D levels (Finland). Cancer Causes Control. 2000 Oct;11(9):847–52.
Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000 Jan 15;60(2):305–8.
A medical hypothesis: phosphorus balance and prostate cancer. Cancer Invest. 2000;18(7):664–9. Review.
1,25-Dihydroxyvitamin D3—a hormone with immunomodulatory properties. Z Rheumatol. 2000;59 Suppl 1:24–7. Review.
Molecular characterisation and racial distribution of androgen and vitamin D receptor polymorphisms in patients with prostate cancer, benign prostatic hyperplasia and age-matched healthy controls. Prostate Cancer Prostatic Dis. 1999 Nov;2(S3):S30.
Phosphorus balance and prostate cancer. Indian J Exp Biol. 1999 Jul;37(7):623–6. Review.
Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999 Jun;221(2):89–98. Review.
20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Anticancer Res. 1999 May–Jun;19(3A):1689–97.
Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control. 1998 Dec;9(6):567–82. Review.
Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control. 1998 Dec;9(6):559–66.
19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res. 1998 Aug 1;58(15):3370–5.
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control. 1998 Aug;9(4):425–32.
Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):391–5.
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):385–90.
Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 1997 Aug;19(1):15–27.
Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996 Sep 15;56(18):4108–10.
Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology. 1996 May;137(5):1554–61.
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):121–6.
Sunlight—can it prevent as well as cause cancer? Cancer Res. 1995 Sep 15;55(18):4014–22. Review.
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control. 1995 May;6(3):235–9.
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20–6.
Vitamin D and prostate cancer. Adv Exp Med Biol. 1995;375:53–63. Review.
Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993 Sep–Oct;2(5):467–72.
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993 May;132(5):1952–60.
Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992 Dec 15;70(12):2861–9.
Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology. 1992;11(4–6):244–54.
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990 Sep–Oct;10(5A):1307–11.
Genetic markers in carcinoma of the prostate. Eur Urol. 1984;10(5):315–6.

back to research menu

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Unless otherwise expressly stated, all site content licensed under a Creative Commons License.